Evaluating the Clinical Utility of the Glycemia Risk Index
The GRI is perceived as a valuable complement to traditional CGM reports, particularly in facilitating quick clinical assessments and furthering diabetes care and education. While enthusiasm for broader integration is high, barriers such as lack of standardization, limited guideline adoption, and HCP training must be addressed to support its clinical uptake. Future work should assess the GRI's impact on clinical outcomes and explore implementation strategies.
Authors
- Yijiong Yang (ORCID: https://orcid.org/0000-0002-6644-4179)
- Ralph Oiknine
- Neesha Ramchandani (ORCID: https://orcid.org/0000-0003-0491-7521)
- Jane Jeffrie Seley (ORCID: https://orcid.org/0000-0003-1582-4320)
- David T. Ahn (ORCID: https://orcid.org/0000-0002-8941-8459)
- David Charles Klonoff (ORCID: https://orcid.org/0000-0001-6394-6862)
- Jing Wang (ORCID: https://orcid.org/0000-0002-4012-0977)
- M. Shao (ORCID: https://orcid.org/0009-0004-9550-9965)
- Agatha F. Scheideman (ORCID: https://orcid.org/0009-0008-4211-4934)
Institutions
- Florida State University (US)
- Northwell Health (US)
- Hoag Memorial Hospital Presbyterian (US)
- Cornell University (US)
- Yale University (US)
- Kids' Brain Tumor Cure Foundation (US)
- Diabetes & Endocrinology Specialists (US)
- Mills Peninsula Health Services (US)
- Diabetes Technology Society (US)
Publication Details
- Journal
- Journal of Diabetes Science and Technology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1177/19322968251382604
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00